Quest Magazine

DMD: Companies To Host Web Presentations on Exon Skipping

Artwork By Missiouri Artist Accepted Into MDA Art Collection

ALS Briefs: NurOwn, Disease Modifiers, Biomarker Test

Quintiles Selected by Muscular Dystrophy Association to Develop U.S. Disease Registry

New Tadalafil Trial in Becker MD Now Open

A new trial of tadalafil (Cialis), a drug that dilates blood vessels, is now under way at Cedars-Sinai Medical Center in Los Angeles for men with Becker muscular dystrophy (BMD) who meet study criteria.

LEMS: Jacobus Expands Trial of 3,4-DAP

Jacobus Pharmaceutical of Princeton, N.J., is continuing its placebo-controlled trial of 3,4-diaminopyridine (3,4-DAP) for people with Lambert-Eaton myasthenic syndrome (LEMS) who have been receiving the drug through Jacbobus' "expanded access" (also called "compassionate use") program. The study, which began in January 2012, was originally by invitation only.

Prosensa Says It Remains Committed to DMD

"Our commitment to Duchenne muscular dystrophy remains," said Hans Schikan, CEO of Netherlands-based biotechnology company Prosensa at a Sept. 27, 2013, presentation in New York.

MDA's Board Chairman Advocates Support for Newborn Screening

UPDATE: DMD: Eteplirsen Shows Continued Benefit at 84 Weeks

Eighth Annual Tradition Of Hope Gala To Support MDA's Augie's Quest